Rosoxacin in the treatment of uncomplicated gonorrhoea in men.

Abstract

Between 3 January and 4 March 1983 we treated 200 male patients diagnosed as having uncomplicated gonococcal urethritis with one of two regimens. They were divided into two groups and randomly assigned to treatment with either 2 g spectinomycin administered intramuscularly (group A) or 300 mg rosoxacin by mouth (group B). Of 187 isolates tested for the production of beta-lactamase, 101 (54%) were penicillinase producing Neisseria gonorrhoeae (PPNG) strains. All 81 cases followed in group A (spectinomycin) were cured, compared with 88.5% (77 out of 87) of the patients followed in group B (rosoxacin). We concluded that rosoxacin at a dosage of 300 mg administered orally was fairly effective in the treatment of gonococcal urethritis in men caused by both PPNG and non-PPNG strains.

• Authors: K Panikabutra, C Ariyarit, A Chitwarakorn, C Saensanoh
• Journal: The British journal of venereal diseases (Br J Vener Dis) Vol. 60 Issue 4 Pg. 231-4 (Aug 1984) ISSN: 0007-134X [Print] England
• PMID: 6234966 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial)

Chemical References

• 4-Quinolones
• Anti-Bacterial Agents
• Quinolines
• Quinolones
• rosoxacin
• Spectinomycin
• Penicillinase

Topics

• 4-Quinolones
• Anti-Bacterial Agents (therapeutic use)
• Gonorrhea (drug therapy)
• Humans
• Male
• Microbial Sensitivity Tests
• Neisseria gonorrhoeae (enzymology)
• Penicillinase (biosynthesis)
• Quinolines (therapeutic use)
• Quinolones
• Spectinomycin (therapeutic use)
• Urethritis (drug therapy)